Dacquin Muhandwa Kasumba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dacquin Muhandwa Kasumba has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Nathalie Grandvaux
Centre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec, H2X0A9, Canada
3 shared publications - Bive Bive Zono
Molecular Biology Service, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
2 shared publications Hiroki Kato
Laboratory of Molecular Genetics, Institute for Frontier Life and Medical Sciences, Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan
2 shared publications- Marie-Pierre Hayette
Clinical Microbiology Laboratory, National Reference Center for Mycosis, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, Liege, 4000, Belgium
2 shared publications - Placide Mbala-Kingebeni
Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2 shared publications Takara Hajake
Laboratory of Molecular Genetics, Institute for Frontier Life and Medical Sciences, Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by American Society for Microbiology in Journal of Virology
Endogenous anti-Ebola virus GP 1,2 antibodies interfere with detection of secreted glycoprotein in the blood of EVD patients
Ebola disease (EBOD) is a highly infectious disease with severe hemorrhagic symptoms. It is caused by orthoebolaviruses , which include the Ebola virus ( Orthoebolavirus zairense ) (EBOV) causing Ebola virus disease (EVD), the most lethal EBOD to humans. Through co-transcriptional polymerase stuttering and subsequent proteolytic processing, its GP gene produces multiple protein products, including secreted glycoprotein (sGP) and structural membrane-associated trimeric GP 1,2 . Although sGP is known to circulate in the blood, its physiological significance in disease pathology remains speculative. We quantified sGP using enzyme-linked immunosorbent assay (ELISA) in 36 acute human EVD cases from the 10th and 11th EVD outbreaks in the Democratic Republic of the Congo (DRC) using single-time-point biobanked samples. We detected and quantified sGP in four patients with strong GP gene transcription (GP Ct < 25), as evidence of viral replication, but with no endogenous anti-EBOV GP 1,2 IgG. However, sGP was not quantified in patients with lower GP transcription (Ct > 25), regardless of their anti-EBOV GP 1,2 IgG results. While two patients, MAM179 and MAM271, had notably strong GP transcription (Ct < 25), their high amounts of endogenous anti-EBOV GP 1,2 IgG might have interfered with detection by the assay detection antibody, a human anti-EBOV GP 1,2 /sGP IgG. Furthermore, the addition of sera containing anti-EBOV GP 1,2 IgG reduced the binding between sGP and anti-EBOV GP 1,2 /sGP used as detection antibodies. This suggested that the level of sGP in circulation is strongly linked to the intensity of GP transcription. Additionally, circulating sGP in this context would form complexes with anti-GP 1,2 antibodies, hence hindering additional antibody binding for detection. IMPORTANCE: Insight into the mechanism of immune function by the Ebola virus secreted glycoprotein (sGP) in humans is essential for better understanding viral pathogenesis, immune protection, and immune evasion strategies. Research utilizing samples from patients who are infected with or have survived infection with the Ebola virus offers an unparalleled opportunity to determine the immunological significance of sGP. This research evaluates, in acutely infected patients from Ebola virus disease outbreaks, the role of EBOV sGP in modulating antibody responses directed against viral entry glycoprotein. By elucidating how sGP influences antibody-mediated immunity, the study advances our understanding of a conserved immune-evasion mechanism shared across all orthoebolaviruses. These investigations are valuable resources for designing more efficacious vaccines, therapies, and biomarkers for monitoring Ebola virus diseases.
- 6 October 2026
- Published by American Society for Microbiology in Journal of Virology
Open AccessEndogenous anti-Ebola virus GP 1,2 antibodies interfere with detection of secreted glycoprotein in the blood of EVD patients
Ebola disease (EBOD) is a highly infectious disease with severe hemorrhagic symptoms. It is caused by orthoebolaviruses , which include the Ebola virus ( Orthoebolavirus zairense ) (EBOV) causing Ebola virus disease (EVD), the most lethal EBOD to humans. Through co-transcriptional polymerase stuttering and subsequent proteolytic processing, its GP gene produces multiple protein products, including secreted glycoprotein (sGP) and structural membrane-associated trimeric GP 1,2 . Although sGP is known to circulate in the blood, its physiological significance in disease pathology remains speculative. We quantified sGP using enzyme-linked immunosorbent assay (ELISA) in 36 acute human EVD cases from the 10th and 11th EVD outbreaks in the Democratic Republic of the Congo (DRC) using single-time-point biobanked samples. We detected and quantified sGP in four patients with strong GP gene transcription (GP Ct < 25), as evidence of viral replication, but with no endogenous anti-EBOV GP 1,2 IgG. However, sGP was not quantified in patients with lower GP transcription (Ct > 25), regardless of their anti-EBOV GP 1,2 IgG results. While two patients, MAM179 and MAM271, had notably strong GP transcription (Ct < 25), their high amounts of endogenous anti-EBOV GP 1,2 IgG might have interfered with detection by the assay detection antibody, a human anti-EBOV GP 1,2 /sGP IgG. Furthermore, the addition of sera containing anti-EBOV GP 1,2 IgG reduced the binding between sGP and anti-EBOV GP 1,2 /sGP used as detection antibodies. This suggested that the level of sGP in circulation is strongly linked to the intensity of GP transcription. Additionally, circulating sGP in this context would form complexes with anti-GP 1,2 antibodies, hence hindering additional antibody binding for detection. IMPORTANCE: Insight into the mechanism of immune function by the Ebola virus secreted glycoprotein (sGP) in humans is essential for better understanding viral pathogenesis, immune protection, and immune evasion strategies. Research utilizing samples from patients who are infected with or have survived infection with the Ebola virus offers an unparalleled opportunity to determine the immunological significance of sGP. This research evaluates, in acutely infected patients from Ebola virus disease outbreaks, the role of EBOV sGP in modulating antibody responses directed against viral entry glycoprotein. By elucidating how sGP influences antibody-mediated immunity, the study advances our understanding of a conserved immune-evasion mechanism shared across all orthoebolaviruses. These investigations are valuable resources for designing more efficacious vaccines, therapies, and biomarkers for monitoring Ebola virus diseases.
- Open Access
- 26 August 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (10)
Operational bottlenecks in the response to Bundibugyo virus disease outbreak in the Democratic Republic of the Congo: a call to action
- 26 August 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (10)
Open AccessOperational bottlenecks in the response to Bundibugyo virus disease outbreak in the Democratic Republic of the Congo: a call to action
- Open Access
A Stable Reporter Cell Line to Study Respiratory Syncytial Virus NS2-Mediated Inhibition of IFNB Promoter Activation
Human respiratory syncytial virus (RSV) is an enveloped, non-segmented, negative-sense RNA virus and a major cause of severe lower respiratory tract disease in infants, older adults, and immunocompromised individuals. A hallmark of RSV pathogenesis is early evasion of innate immunity mediated by the non-structural proteins NS1 and NS2. NS2 is a multifunctional interferon (IFN) antagonist that dampens both IFNβ induction and type I IFN responsiveness by targeting multiple nodes of the RIG-I/IFN signaling axis. Because NS2 inhibition is typically partial and context dependent, its quantitative assessment in conventional cell-based assays can be challenging. Here, we report the generation and characterization of a stable, virus-free reporter system in human lung epithelial A549 cells to measure NS2-mediated inhibition of RIG-I–dependent activation of the human IFNB promoter. The platform combines stable NS2 expression with genomic integration of a dual cassette encoding (i) a non-targeting short hairpin RNA that constitutively activates RIG-I signaling and (ii) a firefly luciferase reporter driven by the IFNB promoter. This configuration provides a sensitive and reproducible luminescence readout of IFNB promoter activity under controlled, infection-free conditions, enabling robust quantification of NS2 antagonism with reduced experimental variability. The luminescence-based format is readily scalable for early-stage discovery and prioritization of small molecules or biologics that counteract NS2 function. More broadly, the modular design can be adapted to other viral immune antagonists, signaling pathways, or cell types, supporting comparative studies where pathway modulation must be evaluated under highly standardized and reproducible conditions.
Open AccessA Stable Reporter Cell Line to Study Respiratory Syncytial Virus NS2-Mediated Inhibition of IFNB Promoter Activation
Human respiratory syncytial virus (RSV) is an enveloped, non-segmented, negative-sense RNA virus and a major cause of severe lower respiratory tract disease in infants, older adults, and immunocompromised individuals. A hallmark of RSV pathogenesis is early evasion of innate immunity mediated by the non-structural proteins NS1 and NS2. NS2 is a multifunctional interferon (IFN) antagonist that dampens both IFNβ induction and type I IFN responsiveness by targeting multiple nodes of the RIG-I/IFN signaling axis. Because NS2 inhibition is typically partial and context dependent, its quantitative assessment in conventional cell-based assays can be challenging. Here, we report the generation and characterization of a stable, virus-free reporter system in human lung epithelial A549 cells to measure NS2-mediated inhibition of RIG-I–dependent activation of the human IFNB promoter. The platform combines stable NS2 expression with genomic integration of a dual cassette encoding (i) a non-targeting short hairpin RNA that constitutively activates RIG-I signaling and (ii) a firefly luciferase reporter driven by the IFNB promoter. This configuration provides a sensitive and reproducible luminescence readout of IFNB promoter activity under controlled, infection-free conditions, enabling robust quantification of NS2 antagonism with reduced experimental variability. The luminescence-based format is readily scalable for early-stage discovery and prioritization of small molecules or biologics that counteract NS2 function. More broadly, the modular design can be adapted to other viral immune antagonists, signaling pathways, or cell types, supporting comparative studies where pathway modulation must be evaluated under highly standardized and reproducible conditions.
- Open Access
- 2 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Screening for cryptococcal antigenemia and meningeal cryptococcosis, genetic characterization of Cryptococcus neoformans in asymptomatic patients with advanced HIV disease in Kinshasa, Democratic Republic of Congo
We evaluated the prevalence of serum and meningeal cryptococcosis in asymptomatic outpatients with advanced HIV disease (CD4 < 200 cells/mm3) in a cross-sectional screening context in Kinshasa clinics (DRC). Lumbar puncture (LP) was performed in patients with positive serum cryptococcal antigen (CrAg) test, and Cryptococcus spp. isolated from cerebrospinal fluid (CSF) were identified by MALDI-TOF-MS, and characterized using serotyping-PCR, ITS-sequencing and multilocus sequence typing (MLST). The genetic profiles obtained were then compared with those of isolates previously described in symptomatic patients in the same clinics. Forty-seven patients with advanced HIV disease out of 262 included were positive for serum CrAg (18%, 95% CI: 14.2–24.3). The prevalence of asymptomatic cryptococcal meningitis (CM) was then measured at 50% among patients with positive serum CrAg test who consented to LP (19/38). Only four CSF samples were culture positive and all were characterized as Cryptococcus neoformans, molecular type VNI and belonging to two different sequence types (ST): ST93 (3/4) and ST63 (1/4). While ST93 is also the main genomic profile described in advanced HIV disease patients with symptomatic CM in Kinshasa clinics, ST63 has not yet been identified in DRC before. It is likely that future studies involving a large number of strains will be necessary before any definitive conclusions can be drawn on the involved strains in asymptomatic patients.
- 2 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open AccessScreening for cryptococcal antigenemia and meningeal cryptococcosis, genetic characterization of Cryptococcus neoformans in asymptomatic patients with advanced HIV disease in Kinshasa, Democratic Republic of Congo
We evaluated the prevalence of serum and meningeal cryptococcosis in asymptomatic outpatients with advanced HIV disease (CD4 < 200 cells/mm3) in a cross-sectional screening context in Kinshasa clinics (DRC). Lumbar puncture (LP) was performed in patients with positive serum cryptococcal antigen (CrAg) test, and Cryptococcus spp. isolated from cerebrospinal fluid (CSF) were identified by MALDI-TOF-MS, and characterized using serotyping-PCR, ITS-sequencing and multilocus sequence typing (MLST). The genetic profiles obtained were then compared with those of isolates previously described in symptomatic patients in the same clinics. Forty-seven patients with advanced HIV disease out of 262 included were positive for serum CrAg (18%, 95% CI: 14.2–24.3). The prevalence of asymptomatic cryptococcal meningitis (CM) was then measured at 50% among patients with positive serum CrAg test who consented to LP (19/38). Only four CSF samples were culture positive and all were characterized as Cryptococcus neoformans, molecular type VNI and belonging to two different sequence types (ST): ST93 (3/4) and ST63 (1/4). While ST93 is also the main genomic profile described in advanced HIV disease patients with symptomatic CM in Kinshasa clinics, ST63 has not yet been identified in DRC before. It is likely that future studies involving a large number of strains will be necessary before any definitive conclusions can be drawn on the involved strains in asymptomatic patients.
- 14 October 2023
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 44 (12) , 857-861
Exploring host–virus interaction to improve immunotherapy against Ebola virus
- 14 October 2023
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 44 (12) , 857-861
Exploring host–virus interaction to improve immunotherapy against Ebola virus
- Open Access
- 7 February 2020
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 27 (8) , 2363-2382
Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death
Host nucleases are implicated in antiviral response through the processing of pathogen-derived nucleic acids. Among many host RNases, decapping enzymes DCP1 and 2, and 5′→3′ exonuclease XRN1, which are components of the RNA decay machinery, have been extensively studied in prokaryotes, plants, and invertebrates but less so in mammalian systems. As a result, the implication of XRN1 and DCPs in viral replication, in particular, the spatio-temporal dynamics during RNA viral infections remains elusive. Here, we highlight that XRN1 and DCPs play a critical role in limiting several groups of RNA viral infections. This antiviral activity was not obvious in wild-type cells but clearly observed in type I interferon (IFN-I)-deficient cells. Mechanistically, infection with RNA viruses induced the enrichment of XRN1 and DCPs in viral replication complexes (vRCs), hence forming distinct cytoplasmic aggregates. These aggregates served as sites for direct interaction between XRN1, DCP1/2, and viral ribonucleoprotein that contains viral RNA (vRNA). Although these XRN1-DCP1/2-vRC-containing foci resemble antiviral stress granules (SGs) or P-body (PB), they did not colocalize with known SG markers and did not correlate with critical PB functions. Furthermore, the presence of 5′ mono- and 5′ triphosphate structures on vRNA was not required for the formation of XRN1-DCP1/2-vRC-containing foci. On the other hand, single-, double-stranded, and higher-ordered vRNA species play a role but are not deterministic for efficient formation of XRN1-DCP1/2 foci and consequent antiviral activity in a manner proportional to RNA length. These results highlight the mechanism behind the antiviral function of XRN1-DCP1/2 in RNA viral infections independent of IFN-I response, protein kinase R and PB function.
- 7 February 2020
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 27 (8) , 2363-2382
Open AccessSpatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death
Host nucleases are implicated in antiviral response through the processing of pathogen-derived nucleic acids. Among many host RNases, decapping enzymes DCP1 and 2, and 5′→3′ exonuclease XRN1, which are components of the RNA decay machinery, have been extensively studied in prokaryotes, plants, and invertebrates but less so in mammalian systems. As a result, the implication of XRN1 and DCPs in viral replication, in particular, the spatio-temporal dynamics during RNA viral infections remains elusive. Here, we highlight that XRN1 and DCPs play a critical role in limiting several groups of RNA viral infections. This antiviral activity was not obvious in wild-type cells but clearly observed in type I interferon (IFN-I)-deficient cells. Mechanistically, infection with RNA viruses induced the enrichment of XRN1 and DCPs in viral replication complexes (vRCs), hence forming distinct cytoplasmic aggregates. These aggregates served as sites for direct interaction between XRN1, DCP1/2, and viral ribonucleoprotein that contains viral RNA (vRNA). Although these XRN1-DCP1/2-vRC-containing foci resemble antiviral stress granules (SGs) or P-body (PB), they did not colocalize with known SG markers and did not correlate with critical PB functions. Furthermore, the presence of 5′ mono- and 5′ triphosphate structures on vRNA was not required for the formation of XRN1-DCP1/2-vRC-containing foci. On the other hand, single-, double-stranded, and higher-ordered vRNA species play a role but are not deterministic for efficient formation of XRN1-DCP1/2 foci and consequent antiviral activity in a manner proportional to RNA length. These results highlight the mechanism behind the antiviral function of XRN1-DCP1/2 in RNA viral infections independent of IFN-I response, protein kinase R and PB function.
- Open Access
The Combination of IFN β and TNF Induces an Antiviral and Immunoregulatory Program via Non-Canonical Pathways Involving STAT2 and IRF9
Interferon (IFN) β and Tumor Necrosis Factor (TNF) are key players in immunity against viruses. Compelling evidence has shown that the antiviral and inflammatory transcriptional response induced by IFNβ is reprogrammed by crosstalk with TNF. IFNβ mainly induces interferon-stimulated genes by the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway involving the canonical ISGF3 transcriptional complex, composed of STAT1, STAT2, and IRF9. The signaling pathways engaged downstream of the combination of IFNβ and TNF remain elusive, but previous observations suggested the existence of a response independent of STAT1. Here, using genome-wide transcriptional analysis by RNASeq, we observed a broad antiviral and immunoregulatory response initiated in the absence of STAT1 upon IFNβ and TNF costimulation. Additional stratification of this transcriptional response revealed that STAT2 and IRF9 mediate the expression of a wide spectrum of genes. While a subset of genes was regulated by the concerted action of STAT2 and IRF9, other gene sets were independently regulated by STAT2 or IRF9. Collectively, our data supports a model in which STAT2 and IRF9 act through non-canonical parallel pathways to regulate distinct pool of antiviral and immunoregulatory genes in conditions with elevated levels of both IFNβ and TNF.
Open AccessThe Combination of IFN β and TNF Induces an Antiviral and Immunoregulatory Program via Non-Canonical Pathways Involving STAT2 and IRF9
Interferon (IFN) β and Tumor Necrosis Factor (TNF) are key players in immunity against viruses. Compelling evidence has shown that the antiviral and inflammatory transcriptional response induced by IFNβ is reprogrammed by crosstalk with TNF. IFNβ mainly induces interferon-stimulated genes by the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway involving the canonical ISGF3 transcriptional complex, composed of STAT1, STAT2, and IRF9. The signaling pathways engaged downstream of the combination of IFNβ and TNF remain elusive, but previous observations suggested the existence of a response independent of STAT1. Here, using genome-wide transcriptional analysis by RNASeq, we observed a broad antiviral and immunoregulatory response initiated in the absence of STAT1 upon IFNβ and TNF costimulation. Additional stratification of this transcriptional response revealed that STAT2 and IRF9 mediate the expression of a wide spectrum of genes. While a subset of genes was regulated by the concerted action of STAT2 and IRF9, other gene sets were independently regulated by STAT2 or IRF9. Collectively, our data supports a model in which STAT2 and IRF9 act through non-canonical parallel pathways to regulate distinct pool of antiviral and immunoregulatory genes in conditions with elevated levels of both IFNβ and TNF.
- 1 August 2019
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 31 (12) , 811-821
Broad and systemic immune-modulating capacity of plant-derived dsRNA
Double-stranded RNA (dsRNA) is well characterized as an inducer of anti-viral interferon responses. We previously reported that dsRNA extracted from a specific edible plant possesses an immune-modulating capacity to confer, in mice, resistance against respiratory viruses, including the H1N1 strain of the influenza A virus (IAV). We report here that the systemic immune-activating capacity of the plant-derived dsRNA protected mice from infection by a highly virulent H5N1 strain of the IAV. In addition, subcutaneous inoculation of the dsRNA together with the inactivated virion of the H5N1 strain of the IAV suppressed the lethality of the viral infection as compared with individual inoculation of either dsRNA or HA protein, suggesting its potential usage as a vaccination adjuvant. Moreover, intra-peritoneal inoculation of the dsRNA limited the growth of B16-F10 melanoma cells through the activation of NK cells in murine models. Taken together, this study demonstrated the systemic immune-modulating capacity of a plant-derived dsRNA and its potential for nucleic acid-based clinical applications.
- 1 August 2019
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 31 (12) , 811-821
Broad and systemic immune-modulating capacity of plant-derived dsRNA
Double-stranded RNA (dsRNA) is well characterized as an inducer of anti-viral interferon responses. We previously reported that dsRNA extracted from a specific edible plant possesses an immune-modulating capacity to confer, in mice, resistance against respiratory viruses, including the H1N1 strain of the influenza A virus (IAV). We report here that the systemic immune-activating capacity of the plant-derived dsRNA protected mice from infection by a highly virulent H5N1 strain of the IAV. In addition, subcutaneous inoculation of the dsRNA together with the inactivated virion of the H5N1 strain of the IAV suppressed the lethality of the viral infection as compared with individual inoculation of either dsRNA or HA protein, suggesting its potential usage as a vaccination adjuvant. Moreover, intra-peritoneal inoculation of the dsRNA limited the growth of B16-F10 melanoma cells through the activation of NK cells in murine models. Taken together, this study demonstrated the systemic immune-modulating capacity of a plant-derived dsRNA and its potential for nucleic acid-based clinical applications.
- 1 February 2019
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 40 (2) , 116-127
Therapeutic Targeting of RIG-I and MDA5 Might Not Lead to the Same Rome
- 1 February 2019
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 40 (2) , 116-127
Therapeutic Targeting of RIG-I and MDA5 Might Not Lead to the Same Rome